Table 3 Study characteristics: Open label R-ketamine trials.
Reference | Study Design; Country; Registration | Sample size (intervention vs control, if applicable) | Control Drug (if applicable) | Population | Intervention | Measure of suicidal ideation or behavior | Main Findings |
---|---|---|---|---|---|---|---|
Bandeira et al. [24] | Open-label pilot trial; Brazil UMIN000042201a | 6 | N/A | 18–65 y/o inpatient and outpatients with depressive episode ( ≥ 4 weeks in duration), type I and II bipolar disorder without psychotic features, a YMRSb of 12 or less at baseline; a MADRSc of at least 25 | IV R-ketamine (0.5 mg/kg) administered over 40 min. After one week, IV R-ketamine (1 mg/kg) over 40 min | MADRSc item 10 | Rapid-acting antidepressant response with 50% improvement one day after the 1.0 mg/kg dose. SI decreased by 60% without severe adverse effects, dissociation, and manic symptoms |
Leal et al. [22] | Open label, pilot-study; Brazil; UMIN000038347d | 7 | N/A | 18–65 y/o inpatients and outpatients with MDD, MADRSc score of at least 25, and failure to respond to at least 2 antidepressant trials in current episode. | Single infusion of IV R-ketamine (0.5 mg/kg) over 40 min | Did not measure suicidal ideation. Depression was measured using the MADRSc. The CADSSd measured dissociative symptoms. | Fast-onset and sustained antidepressant effects from 60 min up to 240 min post-infusion. Limited dissociative symptoms and adverse effects. |